A targeted cancer drug has been approved for use on the NHS in Scotland for patients with advanced, newly diagnosed ovarian cancer that’s responded to chemotherapy. Olaparib (Lynparza) tablets will be used to help prolong the effects of initial treatment, as a so-called maintenance therapy. The targeted therapy is already available in England and for people with advanced ovarian cancer who’ve had 2 or more round of chemotherapy in Scotland, but the latest decision will mean patients can now receive olaparib after their first round of chemotherapy.
See more at: https://www.cancerresearchuk.org/about-us/cancer-news/news-report/2019-12-09-targeted-ovarian-cancer-drug-made-more-widely-available-on-the-nhs-in-scotland
